US FDA, Industry Prepare For Potential Spread Of Surging Demand For Children’s Pain Relief OTCs
FDA “understands that manufacturers expect availability to continue to increase in the near future.” CHPA is working with members “focused on safeguarding the US supply by maximizing capacity to produce and direct product to where it is needed most.”
You may also be interested in...
“We made significant progress towards the separation of Kenvue,” says CEO Jaoquin Duoto. But fourth-quarter and full-year progress on consumer sales growth was impeded by loss to foreign currency exchange.
OTC drug and dietary supplement industry trade group executives discuss questions on potential market and regulatory developments affecting their members’ businesses. HBW Insight begins reporting from those talks with outlook for supply chain nd production disruptions and prevalence of COVID-19 and other widespread viruses.
Demand for OTC pain relievers and cough/cold products jumped prior to October-December and remained high during quarter due to consumer concern not only about flu but also RSV and additional COVID-19 mutation. US and Canadian firms marketing OTC drugs and supplements also will be offering additional signals on planned spinoffs of consumer health businesses.